
June 6 (Reuters) -
OTSUKA SIBEPRENLIMAB PHASE 3 DATA SHOW A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL PROTEINURIA REDUCTION FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
OTSUKA: VISIONARY STUDY CONTINUES IN A BLINDED MANNER TO EVALUATE CHANGE IN KIDNEY FUNCTION OVER 24 MONTHS; EXPECTED TO BE COMPLETED IN EARLY 2026
Further company coverage: [ ]